Phase II Clinical Trial NEO-201 in Combination with Pembrolizumab Detailed Study InformationStrattmont Group
The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody NEO-201 with the anti PD-1 monoclonal antibody Pembrolizumab (KEYTRUDA ®), is open and recruiting patients at the National Cancer Institute, National Institutes of Health (NIH) (USA).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided in the following links:
Clinical Trials.gov https://clinicaltrials.gov/ct2/show/NCT03476681?term=NEO-201&draw=2&rank=1
National Cancer Institute Website https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2021-03638&loc=0&q=NEO-201&rl=1